Chinese Biotech Ascentage Boosts Talent Retention with New Stock Incentives

Rhea-AI Filing Summary

Ascentage Pharma Group International filed a Form 6-K report announcing additional awards granted under its 2021 and 2022 RSU (Restricted Share Unit) Schemes. The report was filed on June 28, 2025, with the announcement dated June 27, 2025.

The filing includes a single exhibit (99.1) containing the detailed announcement of the RSU grants. The document was signed by CEO Dajun Yang. The company, headquartered in Suzhou Industrial Park, China, confirms it files annual reports under Form 20-F.

This filing represents a routine securities disclosure regarding employee compensation arrangements, though specific details of the RSU grants are contained in the referenced exhibit which is not included in the main filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 06/27/2025 - 04:15 PM Learn about SEC filing dates

FAQ

What type of RSU awards did AAPG announce in June 2025?

According to the 6-K filing, Ascentage Pharma Group International (AAPG) announced further grants of awards under both their 2021 RSU Scheme and 2022 RSU Scheme on June 27, 2025. The specific details of the awards are contained in Exhibit 99.1 of the filing.

Who signed AAPG's June 2025 6-K filing?

The 6-K filing was signed by Dajun Yang, who serves as the Chief Executive Officer of Ascentage Pharma Group International, on June 27, 2025.

What is AAPG's principal business location according to the June 2025 6-K?

According to the 6-K filing, Ascentage Pharma Group International's principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.

Which annual reporting form does AAPG use as a foreign issuer?

The 6-K filing indicates that Ascentage Pharma Group International files its annual reports under Form 20-F, as marked in the checkbox on the filing, rather than Form 40-F.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of June 2025

 

Commission File Number: 002-023311

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒            Form 40-F ☐

 

 

 

 

 

 

On June 27, 2025, Ascentage Pharma Group International issued an announcement entitled, “Further Grant of Awards Under The 2021 RSU Scheme and The 2022 RSU Scheme”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.

 

1

 

 

INDEX TO EXHIBITS

 

Exhibit Number 	 	Exhibit Title
99.1	 	Announcement dated June 27, 2025

  

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

 	ASCENTAGE PHARMA GROUP INTERNATIONAL
 	 
Date: June 27, 2025	/s/ Dajun Yang
 	Name: Dajun Yang
 	Title:   Chief Executive Officer

 

 

3